The company’s portfolio includes two programs: OKI-345 for breast cancer and OKI-355 for vascular anomalies. OnKure plans to submit Investigational New Drug applications to the U.S. Food and Drug ...

Tivic Health Systems, Inc. is a biotechnology company developing immunotherapeutic approaches to modulating immune responses. In the past year, the company has shifted its focus to drug development ...

Broadband industry leader Zenita Henderson to align marketing, sales, and partner programs, accelerating AMT’s role in nationwide broadband expansion DEERFIELD ...

Master advanced skills in regulatory communications with a focus on strategy, storytelling, and executive presence. This program combines live virtual sessions and practical exercises, empowering ...

-- Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead’s Inflammation Portfolio -- -- Gilead Intends to Enter into a Strategic ...

Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a total of €5.5m. Funds will be used to further develop Laigo’s SureTACs™ ...

UTRECHT, The Netherlands, March 23, 2026 (GLOBE NEWSWIRE)-- Laigo Bio (“Laigo”), a biotech company pioneering novel and highly differentiated therapies using its proprietary SureTACs™ precision ...

These programs include a high-resolution LiDAR survey to refine structural interpretation and identify subtle topographic and alteration features, a drone-based magnetic survey designed to map ...

There will be an ATL Airport hiring event at Riverside Epi Center in Austell, Ga. on April 18 from 9 a.m. to 2 p.m. This is the first of many hiring events for Hartsfield-Jackson Atlanta International ...

Carlos and Malú Alvarez have committed a $20 million gift to UT San Antonio’s College of Business. The gift from the Alvarez family is the first of its kind in the university’s history and will be ...